MARKET

TNYA

TNYA

Tenaya Therapeutics, Inc.
NASDAQ
0.7347
+0.0232
+3.26%
After Hours: 0.7400 +0.0053 +0.72% 19:54 01/02 EST
OPEN
0.7253
PREV CLOSE
0.7115
HIGH
0.7400
LOW
0.6951
VOLUME
2.16M
TURNOVER
--
52 WEEK HIGH
2.350
52 WEEK LOW
0.3600
MARKET CAP
157.04M
P/E (TTM)
-0.9331
1D
5D
1M
3M
1Y
5Y
1D
Tenaya Therapeutics announces orderly board leadership transition
TipRanks · 2d ago
Tenaya Therapeutics Director David Goeddel Resigns Effective January 2026
Reuters · 2d ago
Weekly Report: what happened at TNYA last week (1222-1226)?
Weekly Report · 12/29/2025 09:09
Weekly Report: what happened at TNYA last week (1215-1219)?
Weekly Report · 12/22/2025 09:09
Analysts Are Bullish on These Healthcare Stocks: Palvella Therapeutics (PVLA), Tenaya Therapeutics (TNYA)
TipRanks · 12/20/2025 15:30
Leerink Partners Reaffirms Their Buy Rating on Tenaya Therapeutics (TNYA)
TipRanks · 12/19/2025 13:55
Tenaya Therapeutics Price Target Cut to $5.00/Share From $6.00 by Canaccord Genuity
Dow Jones · 12/18/2025 18:36
Tenaya Therapeutics Is Maintained at Buy by Canaccord Genuity
Dow Jones · 12/18/2025 18:36
More
About TNYA
Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. Its pipeline includes TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy designed to deliver a working MYBPC3 gene to heart muscle cells via a single intravenous infusion, increasing MyBP-C protein levels to address the underlying cause of MYBPC3-associated HCM with the aim of halting or even reversing disease after a single dose. Its MyPEAK-1 Phase I b/2 clinical trial is an ongoing, multi-center, open-label, dose-escalating study designed to assess the safety, tolerability and clinical efficacy of a one-time intravenous infusion of TN-201 gene replacement therapy. TN-401 is its AAV9-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene.

Webull offers Tenaya Therapeutics Inc stock information, including NASDAQ: TNYA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TNYA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TNYA stock methods without spending real money on the virtual paper trading platform.